Table 2.
Summary of Previous Algorithms Tested for Warfarin Dosing
| Algorithm | Clinical Predictors | Genetic Predictors | Notes |
|---|---|---|---|
| Fixed 35mg Weekly Dose |
- | - | - |
| FDA Dosing Table1 | - | VKORC1-1639 | Used mean of dosing range given. |
| CYP2C9*2 | |||
| CYP2C9*3 | |||
| IWPC (International Warfarin Pharmacogenetics Consortium)2 | Age (in decades) | VKORC1-1639 | - |
| Height | CYP2C9*2 | ||
| Weight | CYP2C9*3 | ||
| Asian | |||
| African American | |||
| Amiodarone | |||
| Enzyme Inducers | |||
| Ramirez et. al.3 | Age (in years) | VKORC1-1639 | - |
| Race | CYP2C9*2 | ||
| Sex | CYP2C9*3 | ||
| Body Surface Area | CYP2C9*6 | ||
| Smoking Status | CYP2C9*8 | ||
| DVT/PE | rs2108622 | ||
| Atrial Fibrillation | rs339097 | ||
| Hernandez et. al.4 | Age (in years) | VKORC1-1639 | Performed on subset of population with genotyping for rs61162043. Missing CYP2C9 rs7089580 due to probe failure. Set all patients to reference allele |
| Weight | VKORC1, | ||
| DVT/PE | rs61162043 | ||
| CYP2C9*2 | |||
| CYP2C9*3 | |||
| CYP2C9*5 | |||
| CYP2C9*8 | |||
| CYP2C9*11 | |||
| rs7089580 | |||
| rs12777823 |
2
Klein et. al. NEJM. 2009;
3
Ramirez et. al. Future Medicine. 2010;
4
Hernandez et. al. The Pharmacogenomics Journal. 2014.